These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34601245)

  • 1. BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project.
    van den Bosch KA; Verberk IMW; Ebenau JL; van der Lee SJ; Jansen IE; Prins ND; Scheltens P; Teunissen CE; Van der Flier WM
    Neurobiol Aging; 2021 Dec; 108():146-154. PubMed ID: 34601245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of BDNF Val66Met Polymorphism on Cognition, Cerebrospinal Fluid, and Neuroimaging Markers in Non-Demented Elderly.
    Xia H; Wang M; Li JQ; Tan CC; Cao XP; Tan L; Yu JT;
    J Alzheimers Dis; 2019; 68(1):405-414. PubMed ID: 30775992
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Boots EA; Schultz SA; Clark LR; Racine AM; Darst BF; Koscik RL; Carlsson CM; Gallagher CL; Hogan KJ; Bendlin BB; Asthana S; Sager MA; Hermann BP; Christian BT; Dubal DB; Engelman CD; Johnson SC; Okonkwo OC
    Neurology; 2017 May; 88(22):2098-2106. PubMed ID: 28468845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
    Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
    J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of APOE and BDNF Val66Met Gene Polymorphisms on Cognitive Functions in Patients with Amnestic Mild Cognitive Impairment.
    Cechova K; Andel R; Angelucci F; Chmatalova Z; Markova H; Laczó J; Vyhnalek M; Matoska V; Kaplan V; Nedelska Z; Ward DD; Hort J
    J Alzheimers Dis; 2020; 73(1):247-257. PubMed ID: 31771052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomere shortening reflecting physical aging is associated with cognitive decline and dementia conversion in mild cognitive impairment due to Alzheimer's disease.
    Koh SH; Choi SH; Jeong JH; Jang JW; Park KW; Kim EJ; Kim HJ; Hong JY; Yoon SJ; Yoon B; Kang JH; Lee JM; Park HH; Ha J; Suh YJ; Kang S
    Aging (Albany NY); 2020 Mar; 12(5):4407-4423. PubMed ID: 32126022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington KD; Bourgeat P; Salvado O; Darby D; Snyder PJ; Bush AI; Martins RN; Masters CL; Rowe CC; Nathan PJ; Maruff P;
    Neurobiol Aging; 2013 Nov; 34(11):2457-64. PubMed ID: 23769397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project.
    Verberk IMW; Hendriksen HMA; van Harten AC; Wesselman LMP; Verfaillie SCJ; van den Bosch KA; Slot RER; Prins ND; Scheltens P; Teunissen CE; Van der Flier WM
    Neurobiol Aging; 2020 May; 89():99-107. PubMed ID: 32081465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.
    Lim YY; Hassenstab J; Goate A; Fagan AM; Benzinger TLS; Cruchaga C; McDade E; Chhatwal J; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield P; Morris JC; Maruff P; Bateman RJ;
    Ann Neurol; 2018 Sep; 84(3):424-435. PubMed ID: 30014553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
    Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
    Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory.
    Kim A; Fagan AM; Goate AM; Benzinger TL; Morris JC; Head D;
    Cogn Affect Behav Neurosci; 2015 Sep; 15(3):625-43. PubMed ID: 25784293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The implication of BDNF Val66Met polymorphism in progression from subjective cognitive decline to mild cognitive impairment and Alzheimer's disease: a 9-year follow-up study.
    Bessi V; Mazzeo S; Bagnoli S; Padiglioni S; Carraro M; Piaceri I; Bracco L; Sorbi S; Nacmias B
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):471-482. PubMed ID: 31560105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of BDNF Val66Met polymorphism on regional white matter hyperintensities and cognitive function in elderly males without dementia.
    Huang CC; Liu ME; Chou KH; Yang AC; Hung CC; Hong CJ; Tsai SJ; Lin CP
    Psychoneuroendocrinology; 2014 Jan; 39():94-103. PubMed ID: 24275008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between brain-derived neurotrophic factor (BDNF) gene polymorphisms and executive function in Japanese patients with Alzheimer's disease.
    Nagata T; Shinagawa S; Nukariya K; Ochiai Y; Kawamura S; Agawa-Ohta M; Kasahara H; Nakayama K; Yamada H
    Psychogeriatrics; 2011 Sep; 11(3):141-9. PubMed ID: 21951954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Laws SM; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Rembach A; Martins RN; Rowe CC; Masters CL; Maruff P
    Mol Psychiatry; 2015 Nov; 20(11):1322-8. PubMed ID: 25288138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
    Ebenau JL; Timmers T; Wesselman LMP; Verberk IMW; Verfaillie SCJ; Slot RER; van Harten AC; Teunissen CE; Barkhof F; van den Bosch KA; van Leeuwenstijn M; Tomassen J; Braber AD; Visser PJ; Prins ND; Sikkes SAM; Scheltens P; van Berckel BNM; van der Flier WM
    Neurology; 2020 Jul; 95(1):e46-e58. PubMed ID: 32522798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.
    Dang C; Harrington KD; Lim YY; Ames D; Hassenstab J; Laws SM; Yassi N; Hickey M; Rainey-Smith SR; Robertson J; Rowe CC; Sohrabi HR; Salvado O; Weinborn M; Villemagne VL; Masters CL; Maruff P;
    Arch Clin Neuropsychol; 2019 Jul; 34(5):585-598. PubMed ID: 30272115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
    Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
    Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects.
    Li G; Peskind ER; Millard SP; Chi P; Sokal I; Yu CE; Bekris LM; Raskind MA; Galasko DR; Montine TJ
    PLoS One; 2009; 4(5):e5424. PubMed ID: 19412541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.